Information Provided By:
Fly News Breaks for December 10, 2019
Dec 10, 2019 | 07:18 EDT
Mizuho analyst Difei Yang raised her price target for uniQure to $90 from $67 saying data presented from AMT-061 in hemophilia B "continues to impress." The data reinforces the analyst's view that uniQure has a "highly differentiated" gene therapy platform. She reiterates a Buy rating on the shares.
News For QURE From the Last 2 Days
There are no results for your query QURE